|
|
|
| Effects of Sevilamer Carbonate on HO-1、iPTH、FGF-23 and Calcium and Phosphorus Metabolism in Patients with Chronic Renal Failure Complicated with Hyperphosphatemia |
| WANG Hui, LIU Fang, CHEN Cheng |
| Department of Blood Purification, Wuhan Red Cross Hospital, Wuhan Hubei 430000 |
|
|
|
|
Abstract 【Objective】To investigate the effects of sevilamer carbonate on heme oxidase-1(HO-1), fibroblast growth factor 23(FGF-23), whole-segment parathyroid hormone (iPTH) and calcium and phosphorus metabolism in patients with chronic renal failure (CRF) complicated with hyperphosphatemia.【Methods】From July 2015 to January 2017, 70 patients with CRF complicated with hyperphosphatemia in our hospital were selected and divided into control group and observation group according to different treatment methods. The control group was treated with conventional hemodialysis, while the observation group was treated with sevilamer carbonate on the basis of the control group. The levels of HO-1, iPTH, FGF-23, calcium and phosphorus metabolism and clinical efficacy of the two groups before and after treatment were compared.【Results】The total effective rate of the observation group was 91.42%, which was significantly higher than 68.57% of the control group (P<0.05). There was no significant difference in the levels of calcium, phosphorus, HO-1, iPTH and FGF-23 between the two groups before treatment (P>0.05); after treatment, the levels of phosphorus, HO-1, iPTH and FGF-23 in the observation group were significantly lower than those in the control group, and the calcium level was significantly higher than that in the control group, with statistical significance (P<0.05). The incidence of complications in the observation group was 11.43%, which was significantly higher than that in the control group (20.00%), and the difference was not statistically significant (P>0.05) 【Conclusion】Sevilamer carbonate combined with hemodialysis in the treatment of CRF patients with hyperphosphatemia can effectively reduce the levels of HO-1, iPTH and FGF-23, regulate the metabolism of calcium and phosphorus, and have low complications, which is worthy of clinical application.
|
|
Received: 06 November 2018
|
|
|
|
|
|
[1] 于庆飞.肾衰宁胶囊对维持性血液透析24例患者钙磷代谢及甲状旁腺激素的影响[J].中国中西医结合肾病杂志,2017,18(7):632-633.
[2] 张万超.肾衰宁联合药用炭片治疗血液透析患者高磷血症的疗效观察[J].临床肾脏病杂志,2016,16(2):106-109.
[3] 刘玺,刘芳,缪蕙,等.口服磷结合剂对老年维持性血液透析患者钙磷代谢及血管钙化的影响[J].河北医药,2018,40(10):1509-1512.
[4] 郑慧,刘智楠.碳酸司维拉姆在慢性肾功能不全合并高磷血症患者治疗中的应用[J].山东医药,2016,56(14):70-71.
[5] 陈香美,倪兆慧,刘玉宁,等.慢性肾衰竭中西医结合诊疗指南[J].中国中西医结合杂志,2015,35(9):1029-1033.
[6] 邹宝林,黄燕林,郭阳化,等.维持性血液透析高磷血症患者低磷饮食行为改变阶段健康信念调查[J].广东医学,2017,38(14):2206-2208.
[7] 江艳,黄珍伦,聂凌,等.碳酸镧治疗尿毒症维持性血液透析患者高磷血症的临床观察[J].中国药房,2017,28(20):2787-2789.
[8] 石敏,周莉,付平,等.慢性肾脏病高磷血症肾损伤机制的研究进展[J].中国中西医结合肾病杂志,2016,17(1):76-78.
[9] 邱丹丹,蒋松,潘瑜,等.血磷水平与糖尿病肾病患者肾脏损伤及远期预后的关系[J].肾脏病与透析肾移植杂志,2016,25(3):208-213.
[10] Oka Y, Matsuda H, Miyazaki M. Authors should pay attention to the confounding by indication of observational study using propensity score [J].Ther Apher Dial,2018, 22(1):95-96.
[11] 郭立华,张静,邢艳丽,等.血液透析患者胃肠道症状与高磷血症的临床研究[J].河北医药,2017,39(17):2675-2677.
[12] 蔡震川,李培贵,张万军,等.碳酸镧与醋酸钙治疗维持性透析患者高磷血症的对比研究[J].实用医院临床杂志,2018,15(3):175-178.
[13] Koiwa F, Yokoyama K, Fukagawa M, et al. Efficacy and safety of sucroferric oxyhydroxide and calcium carbonate in hemodialysis patients[J].Kidney Int Rep,2018, 3(1):185-192.
[14] 姜鸿,庄晶,张长荣,等.司维拉姆对规律血液透析高磷血症患者血清炎症因子水平的影响[J].现代生物医学进展,2016,16(35):6919-6922.
[15] 刘智楠,郑慧,郭向辉.碳酸司维拉姆联合常规治疗对慢性肾衰竭合并高磷血症患者血清炎症因子及HO-1、iPTH水平的影响[J].中国药房,2018,29(5):683-686.
[16] 罗丹,林彬,张浩,等.高通量血液透析对尿毒症患者血清磷及iPTH清除的疗效观察[J].重庆医学,2016,45(22):3137-3139.
[17] 杜娟,夏维波.成纤维细胞生长因子-23的代谢调控及与疾病的关系[J].国际内分泌代谢杂志,2017,37(2):123-127.
[18] 杨玲.司维拉姆治疗维持性血液透析患者高磷血症疗效及安全性Meta分析[J].临床肾脏病杂志,2018,18(2):82-86. |
| [1] |
. [J]. JOURNAL OF CLINICAL RESEARCH, 2020, 37(8): 1248-1250. |
|
|
|
|
2020, Vol. 37 
